Last reviewed · How we verify
pramlintide acetate (Symlin)
pramlintide acetate (Symlin) is a Amylin receptor agonist Small molecule drug developed by AstraZeneca. It is currently FDA-approved for Type 1 diabetes mellitus (adjunct to insulin therapy), Type 2 diabetes mellitus (adjunct to insulin therapy). Also known as: Symlin.
Pramlintide is a synthetic analog of amylin that slows gastric emptying, suppresses glucagon secretion, and promotes satiety to reduce postprandial glucose excursions in diabetes.
Pramlintide acetate, also known as Symlin, is a protein-based agonist that targets the amylin receptor AMY1, CALCR/RAMP1. It is used to treat various conditions, including diabetes mellitus, type 1 diabetes, type 2 diabetes, and obesity, as studied in clinical trials.
At a glance
| Generic name | pramlintide acetate (Symlin) |
|---|---|
| Also known as | Symlin |
| Sponsor | AstraZeneca |
| Drug class | Amylin receptor agonist |
| Target | Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 3) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Pramlintide mimics the natural hormone amylin, which is co-secreted with insulin by pancreatic beta cells. It acts on amylin receptors to modulate three key postprandial processes: delaying stomach emptying to slow nutrient absorption, inhibiting glucagon release to prevent hepatic glucose production, and enhancing satiety signals to reduce food intake. These combined effects lower postmeal blood glucose spikes in patients with type 1 and type 2 diabetes.
Approved indications
- Type 1 diabetes mellitus (adjunct to insulin therapy)
- Type 2 diabetes mellitus (adjunct to insulin therapy)
Common side effects
- Nausea
- Vomiting
- Anorexia
- Hypoglycemia
- Headache
- Abdominal pain
Key clinical trials
- Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide (NA)
- Amylin-Induced Migraine Attacks Without Aura (NA)
- Hypersensitivity to Amylin in Post-Traumatic Headache (NA)
- Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease (EARLY_PHASE1)
- Tailoring Obesity Treatment Trial (PHASE2, PHASE3)
- A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes (PHASE2, PHASE3)
- Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D (PHASE2)
- The Role of Amylin in Bone Metabolism (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pramlintide acetate (Symlin) CI brief — competitive landscape report
- pramlintide acetate (Symlin) updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about pramlintide acetate (Symlin)
What is pramlintide acetate (Symlin)?
How does pramlintide acetate (Symlin) work?
What is pramlintide acetate (Symlin) used for?
Who makes pramlintide acetate (Symlin)?
Is pramlintide acetate (Symlin) also known as anything else?
What drug class is pramlintide acetate (Symlin) in?
What development phase is pramlintide acetate (Symlin) in?
What are the side effects of pramlintide acetate (Symlin)?
What does pramlintide acetate (Symlin) target?
Related
- Drug class: All Amylin receptor agonist drugs
- Target: All drugs targeting Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 3)
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus (adjunct to insulin therapy)
- Indication: Drugs for Type 2 diabetes mellitus (adjunct to insulin therapy)
- Also known as: Symlin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing